The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Yellox bromfenac | Bausch + Lomb Ireland Limited | Pain, Postoperative; Ophthalmologic Surgical Procedures | 🇪🇺 EU 2011-05-18 | Order → |
| Methylthioninium chloride Proveblue methylthioninium chloride | Provepharm SAS | Methemoglobinemia | 🇪🇺 EU 2011-05-06 | Order → |
| Hizentra human normal immunoglobulin (SCIg) | CSL Behring GmbH | Immunologic Deficiency Syndromes | 🇪🇺 EU 2011-04-14 | Order → |
| Pravafenix fenofibrate;pravastatin | Laboratoires SMB S.A. | Dyslipidemias | 🇪🇺 EU 2011-04-14 | Order → |
| Rasilamlo aliskiren hemifumarate;amlodipine besilate | Novartis Europharm Ltd | Hypertension | 🇪🇺 EU 2011-04-14 | Order → |
| Riprazo HCT aliskiren;hydrochlorothiazide | Novartis Europharm Ltd. | Hypertension | 🇪🇺 EU 2011-04-13 | Order → |
| Trobalt retigabine | Glaxo Group Limited | Epilepsy | 🇪🇺 EU 2011-03-27 | Order → |
| Gilenya fingolimod | Novartis Europharm Limited | Multiple Sclerosis | 🇪🇺 EU 2011-03-17 | Order → |
| Halaven eribulin | Eisai GmbH | Breast Neoplasms; Liposarcoma | 🇪🇺 EU 2011-03-17 | Order → |
| Jevtana cabazitaxel | Sanofi Winthrop Industrie | Prostatic Neoplasms | 🇪🇺 EU 2011-03-17 | Order → |
| Repso leflunomide Generic | Teva B.V. | Arthritis, Rheumatoid; Arthritis, Psoriatic | 🇪🇺 EU 2011-03-14 | Order → |
| Teysuno tegafur;gimeracil;oteracil | Nordic Group B.V. | Stomach Neoplasms | 🇪🇺 EU 2011-03-14 | Order → |
| Leflunomide Teva leflunomide Generic | Teva Pharma B.V. | Arthritis, Rheumatoid | 🇪🇺 EU 2011-03-10 | Order → |
| Ifirmacombi irbesartan;hydrochlorothiazide Generic | KRKA tovarna zdravil d.d. Novo mesto | Hypertension | 🇪🇺 EU 2011-03-04 | Order → |
| Pumarix pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) Exceptional circumstances | GlaxoSmithKline Biologicals S.A. | Influenza, Human; Immunization; Disease Outbreaks | 🇪🇺 EU 2011-03-04 | Order → |
| Xeplion paliperidone | Janssen-Cilag International | Schizophrenia | 🇪🇺 EU 2011-03-04 | Order → |
| Daliresp roflumilast | AstraZeneca AB | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2011-02-28 | Order → |
| Esbriet pirfenidone | H.A.C. Pharma | Idiopathic Pulmonary Fibrosis; Lung Diseases; Respiratory Tract Diseases | 🇪🇺 EU 2011-02-28 | Order → |
| Lamivudine/Zidovudine Teva lamivudine;zidovudine Generic | Teva Pharma B.V. | HIV Infections | 🇪🇺 EU 2011-02-28 | Order → |
| Libertek roflumilast | AstraZeneca AB | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2011-02-28 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.